SHYNDEC(SH:600420) news flash·2025-06-04 09:10Core Viewpoint - The company Guoyao Modern (600420) has received approval from the National Medical Products Administration for the registration of its product, Lisinopril Tablets, which is indicated for the treatment of primary hypertension and secondary hypertension due to renal parenchymal disease [1] Summary by Relevant Categories Product Approval - Guoyao Modern's wholly-owned subsidiary, Guoyao Rongseng, has obtained the drug registration certificate for Lisinopril Tablets, enhancing the company's competitiveness in the cardiovascular medication market [1] Market Potential - According to the Minet database, the projected sales for Lisinopril Tablets in public medical institutions across the country for 2024 is estimated at RMB 25.45 million [1] R&D Investment - The cumulative research and development investment for this project by Guoyao Rongseng amounts to approximately RMB 7.717 million [1] Financial Impact - The approval of the drug registration certificate is not expected to have a significant impact on the company's current operating performance [1]